Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Jasper Therapeutics, Inc. (JSPR) had Return on Tangible Equity of -50.28% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-21.24M |
|
-- |
|
-- |
|
$21.80M |
|
$-21.80M |
|
$0.56M |
|
$-21.24M |
|
$-21.24M |
|
$-21.24M |
|
$-21.24M |
|
$-21.24M |
|
$-21.24M |
|
$-21.80M |
|
$-21.52M |
|
15.02M |
|
15.02M |
|
$-1.41 |
|
$-1.41 |
|
| Balance Sheet Financials | |
$53.17M |
|
$1.60M |
|
$4.42M |
|
$57.60M |
|
$12.33M |
|
-- |
|
$3.02M |
|
$15.35M |
|
$42.24M |
|
$42.24M |
|
$42.24M |
|
15.02M |
|
| Cash Flow Statement Financials | |
$-22.84M |
|
$0.00M |
|
-- |
|
$72.05M |
|
$49.22M |
|
$-22.84M |
|
$1.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-22.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-50.28% |
|
|
Return on Tangible Equity |
-50.28% |
-36.88% |
|
-50.28% |
|
$2.81 |
|
$-1.52 |
|
$-1.52 |
|